Related references
Note: Only part of the references are listed.Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis A PRISMA-compliant network meta-analysis
Mei-Juan Li et al.
MEDICINE (2017)
Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Meta-Analysis and GRADE system
Chao Zhang et al.
SCIENTIFIC REPORTS (2017)
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
T. Kagami et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Psychological factors influence the gastroesophageal reflux disease (GERD) and their effect on quality of life among firefighters in South Korea
Seung-Ho Jang et al.
INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
Tu1052 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to Lansoprazole (15 mg Once-Daily) in a 24-Week Maintenance Treatment for Healed Erosive Esophagitis
Eiji Umegaki et al.
GASTROENTEROLOGY (2014)
Evidence Synthesis for Decision Making 1: Introduction
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression
Ian R. White et al.
RESEARCH SYNTHESIS METHODS (2012)
Systematic review of the epidemiology of gastroesophageal reflux disease in Japan
Yoshikazu Kinoshita et al.
JOURNAL OF GASTROENTEROLOGY (2011)
A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals
Yasunobu Hori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis
D. C. Metz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Modeling between-trial variance structure in mixed treatment comparisons
Guobing Lu et al.
BIOSTATISTICS (2009)
Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine
David A. Peura et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
Epidemiology and clinical characteristics of GERD in the Japanese population
Yasuhiro Fujiwara et al.
JOURNAL OF GASTROENTEROLOGY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
A Randomized, Comparative Trial of a Potassium-Competitive Acid blocker (AZD0865)and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease
John Dent et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Gastro-esophageal reflux disease: the recent trend in Japan
Hiroto Miwa et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2008)
Maintenance of healed erosive esophagitis: A randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams
Kenneth R. Devault et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
CYP2C19 genotype and the PPIs - focus on rabeprazole
PWY Lim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States
A Caos et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Updated guidelines for the diagnosis and treatment of Gastroesophageal reflux disease
KR DeVault et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Prevention of erosive oesophagitis relapse with pantoprazole
JE Richter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis:: Metropole study results
K Lauritsen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis
DC Metz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Natural history of nonerosive reflux disease - Is all gastroesophageal reflux disease the same? What is the evidence?
GR Locke
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2002)
Bayesian measures of model complexity and fit
DJ Spiegelhalter et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2002)
The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety
NB Vakil et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease
C Birbara et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2000)
Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease - A double-blind, multicenter, European trial
B Thjodleifsson et al.
DIGESTIVE DISEASES AND SCIENCES (2000)
Share Paper
